Welcome to our dedicated page for Global Innovative Platforms SEC filings (Ticker: GIPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Global Innovative Platforms Inc. filings document its VOCAM Plus breathomics diagnostic technology, Regulation FD investor presentations, and material agreements involving diagnostic units and related support services. The company’s Form 8-K disclosures also cover analytical findings related to canine heartworm breath profiles and corporate matters such as changes in its certifying accountant.
Additional filings include Form 12b-25 late-filing notices for annual reporting, emerging growth company status disclosures, and statements that the company has no securities registered under Section 12(b) of the Exchange Act.
Global Innovative Platforms Inc. issued a shareholder update highlighting progress at VetBreath Analytics across funding, regulation, science, and partnerships. The company reports having enough capital to operate through the end of 2026 after completing a Regulation A offering in March 2026.
The update notes a 15c2-11 application submitted to FINRA on June 12, 2026, an eight-month heartworm study begun April 1, 2026, and development of four additional parasite breath signatures. Revenue for the six months ended March 31, 2026 was $136,500, supported by a collaboration generating about $15,000–$18,000 per month.
Global Innovative Platforms also expanded its Board and Strategic Advisory Board with experienced commercial, governance, and veterinary leaders, added new clinical development expertise, joined and won a Plug and Play incubator pitch competition, and launched a high-volume sample collection collaboration with Big Dog Ranch Rescue.
Global Innovative Platforms Inc. director and CEO/CFO Andrew Nicholas Brown reported two open-market purchases of common stock. He bought 250,000 shares on December 31, 2025 at $0.002 per share and another 250,000 shares on March 31, 2026 at $0.12 per share, for total purchases of 500,000 shares. After the most recent transaction, he directly owns 1,081,055 common shares.
Global Innovative Platforms Inc. reports that James C. Jones beneficially owns 92,812 shares of Common Stock, representing 14.99% of the class. The filing states the Reporting Person acquired the 92,812 shares in a purchase on 03/31/2021 and holds sole voting and dispositive power over those shares.
The disclosure lists the issuer's principal office in Maitland, Florida and provides the CUSIP 13767J104. The signature on the filing is dated 06/09/2026.
Global Innovative Platforms Inc. shareholder Jones James Carl, identified as a ten percent owner, filed a Form 4 that reports no insider transactions or holdings for the period covered. This appears to be an administrative insider ownership filing rather than a report of new share purchases, sales, or option exercises.
Global Innovative Platforms Inc. director Jones James Carl filed an initial Form 3 reporting his beneficial ownership. The filing shows indirect ownership of 1,171,012 shares of Common Stock held through the James C Jones Law Office. This is a disclosure of existing holdings rather than a new stock purchase or sale.
Global Innovative Platforms Inc. filed an initial insider ownership report showing that James Carl Jones is a ten percent owner. The filing lists indirect ownership of 92,812 shares of common stock held through the James C Jones 401(k) plan, with no specific buy or sell transaction reported.
Global Innovative Platforms Inc. disclosed that major shareholder David A B Brown, acting as trustee for his IRA, made a series of open-market purchases of common stock. Across six transactions from October 2023 through June 2025, the IRA acquired a total of 6,682,800 shares, including multiple 250,000-share trades at $0.002 per share and a 2,000,000-share trade at $0.10 per share. Following the most recent purchase on June 30, 2025, Brown’s IRA indirectly holds 6,775,612 shares of Global Innovative Platforms common stock.
Global Innovative Platforms Inc. expanded its board of directors from one to four members, effective April 1, 2026, and appointed Elyssa Jacob Campbell, James C. Jones, Anthony (Tony) Porter, and David Mauer as directors.
The new directors bring experience in animal health research, legal practice, healthcare operations, business development, and partnership management, aligning with the company’s focus on innovative breath-based diagnostics for animal health. The company states there are no family relationships, appointment-related arrangements, or related-party transactions requiring disclosure, and that any committee assignments or director compensation will be detailed in a later filing.
Global Innovative Platforms Inc. reported its first revenues while remaining deeply loss-making and dependent on new funding. For the quarter ended March 31, 2026, the company generated $106,500 in revenue, all from a single animal-health customer using its VOCAM Plus diagnostic technology, and posted a net loss of $151,386. For the six-month period, revenue totaled $136,500 with a net loss of $200,815. Cash and cash equivalents rose to $327,270 and total assets to $591,958, largely funded by $514,354 of common stock proceeds, while liabilities stayed minimal at $2,284. The accumulated deficit reached $1,456,279, and management and the auditors highlight substantial doubt about the company’s ability to continue as a going concern without additional debt or equity financing. As of May 15, 2026, there were 49,103,241 common shares outstanding, reflecting continued equity issuance to investors and service providers.
Global Innovative Platforms Inc. submitted a Form 12b-25 notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company states additional time is needed to complete financial statements, disclosures and allow review by its independent auditor, and expects to file the Form 10-Q in accordance with Rule 12b-25, no later than the fifth calendar day following the prescribed due date.
The notification is signed by Andrew Brown, Chief Executive Officer and dated May 18, 2026.